Subscribe to RSS
Download PDF
DOI: 10.1055/a-2076-0202
Nephropathie bei Diabetes
Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.
Neuerung 1: Überblick zur Diagnostik und den daraus resultierenden Maßnahmen bei Menschen mit Diabetes und CKD
Begründung: Neue Leitlinien
Stützende Quellenangabe: [3] [4]
Neuerung 2: Neues Therapiekapitel zur gezielten medikamentösen Progressionshemmung
Begründung: Neue Zulassungen in Deutschland sowie neuere Daten zu SGLT2-Hemmern
Stützende Quellenangabe: (u. a.) [16]
Neuerung 3: Einsatz von Finerenon als nichtsteroidaler Mineralokortikoid-Rezeptorantagonist bei Typ-2-Diabetes und CKD
Begründung: Neue Zulassung in Deutschland
Stützende Quellenangabe: [17]
Neuerung 4: Aktualisierte Übersicht zur Zulassung von Antidiabetika bei chronischer Niereninsuffizienz in Deutschland
Begründung: Neue Zulassungen in Deutschland, neue Therapieprinzipien
Stützende Quellenangabe: (u. a.) [16]
Publication History
Article published online:
30 October 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673-675
- 2 Kidney Disease: Improving Global Outcomes (KDIGO). CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Supplements 2013; 3: 1-150 . Im Internet (Stand: 25.07.2023): https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
- 3 de Boer IH, Khunti K, Sadusky T. et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45: 3075-3090
- 4
Rossing P,
Caramori ML,
Chan JCN.
et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney
Disease. Kidney Int 2022; 102: S1-S127
MissingFormLabel
- 5 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J 2018; 39: 3021-3104
- 6 Cheung AK, Chang TI, Cushman WC. et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99: S1-S87
- 7
Davies MJ,
Aroda VR,
Collins BS.
et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by
the American Diabetes Association (ADA) and the European Association for the Study
of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786
MissingFormLabel
- 8 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 2022; 17 (Suppl. 02) S159-S204
- 9 Bally L, Gubler P, Thabit H. et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int 2019; 96: 593-596
- 10 Boughton CK, Tripyla A, Hartnell S. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med 2021; 27: 1471-1476
- 11 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
- 12 Sattar N, Lee MMY, Kristensen SL. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653-662
- 13 Baigent C, Emberson JR. et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet 2022; 400: 1788-1801
- 14
Perkovic V,
Jardine MJ,
Neal B.
et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl
J Med 2019; 380: 2295-2306
MissingFormLabel
- 15
Heerspink HJL,
Stefánsson BV,
Correa-Rotter R.
et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:
1436-1446
MissingFormLabel
- 16
The EMPA-KIDNEY Collaborative Group.
Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
MissingFormLabel
- 17 Agarwal R, Filippatos G, Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484